Corrs is representing Tasmanian Alkaloids in relation to various aspects of its technology for genetically-engineered narcotic (opium) poppies. These are processed to prepare narcotic actives that are used in the manufacture of pharmaceutical products for pain relief. In a novel action, our client is seeking preliminary discovery of documents and records from TPI, based on a belief that it may have a claim of patent infringement against TPI, relating to a possible unauthorised early planting of a seed crop to increase volumes of seed for commercial purposes.
Advising on patent infringement, extension and validity litigation against four generic pharmaceutical companies in a dispute relating to an anti-depressant sold as Lexapro. This 14-year-old matter has been running in both the Patent Office with success on liability and damages in the Federal Court.
Advising Merck on patent litigation with Wyeth seeking to revoke patents covering Wyeth’s Prevnar 13 products (vaccines that reduce the incidence of severe ear infections in children, and pneumonia in the elderly). Wyeth has alleged infringement of these patents by the proposed launch of Merck’s own 15-valent vaccine.